Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Data on cancer vaccines published by researchers at Methodist Hospital
December 9th, 2008
Data detailed in 'Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial' have been presented. According to recent research published in the journal Clinical Cancer Research, "The attenuated vaccinia virus modified vaccinia ankara (MVA) has been engineered to deliver the tumor antigen 5T4 (TroVax). TroVax has been evaluated in an open-label phase II trial in metastatic renal cell cancer patients in which the vaccine was administered in combination with interleukin-2 (IL-2)." "The safety, immunologic, and clinical efficacy of TroVax in combination with IL-2 was...
Source: Cancer Weekly (2008-12-09)
|
